Moreover, aberrant expressions of IFITM1 detected through cancer array profiling, immunohistochemistry, RT-PCR, immunoblotting, and immunofluorescence analysis were verified in colorectal cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma (HNSCC), gallbladder, and ovarian cancer (6, 8, 23, 44–46). This evidence concerns the gene IFITM1 and cancer.